Literature DB >> 11218894

[Treatment of intrauterine growth retardation with magnesium sulfate].

Y Tan1, W Zhang, B Lu.   

Abstract

OBJECTIVE: To study the relationship between magnesium level in umbilical vein and mother's peripheral blood with intrauterine growth retardation (IUGR) and fetal weight.
METHODS: 39 pregnant women with IUGR were randomly divided into 3 groups: Group 1 (n = 14): The patients were treated with 10% glucose 500 ml + danshen compound 14 ml + low molecular weight dextran 500 ml i.v.; Group 2 (n = 14): in addition to the same treatment as in group 1, 25% magnesium sulfate 20 ml in 5% glucose 500 ml i.v. was given; Group 3 (n = 11): no treatment was given; and another 12 normal term delivery women were served as control. Magnesium concentration levels were determined in both maternal peripheral blood and their fetal umbilical vein.
RESULTS: Maternal serum magnesium level was higher in Group 2 (1.06 +/- 0.09) mmol/L than that in Group 1 (0.69 +/- 0.05) mmol/L (P < 0.05), while there was no significant difference between Group 1 and Group 3. The serum magnesium levels in both mother and fetal umbilical vein of normal pregnancy and of Group 2 were significantly higher than those of Group 1 and 3 (P < 0.01), so did the birth weight of their newborns (P < 0.05).
CONCLUSION: Magnesium deficiency might be one of the causes of IUGR, and magnesium sulfate treatment was effective.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11218894

Source DB:  PubMed          Journal:  Zhonghua Fu Chan Ke Za Zhi        ISSN: 0529-567X


  2 in total

1.  The effects of magnesium sulfate on fetal rats of FGR and the expression of caspase-3 in the placenta of maternal rat.

Authors:  Hui Gao; Li Zou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 2.  The Role of Magnesium in Pregnancy and in Fetal Programming of Adult Diseases.

Authors:  Daniela Fanni; C Gerosa; V M Nurchi; M Manchia; L Saba; F Coghe; G Crisponi; Y Gibo; P Van Eyken; V Fanos; G Faa
Journal:  Biol Trace Elem Res       Date:  2020-12-14       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.